Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Zai Lab’s latest 10-K means wading through hundreds of pages on oncology trial endpoints, milestone royalties, and cross-border licensing terms. Finding when executives file Form 4s before a key Phase III read-out can be equally demanding. Stock Titan’s AI-powered SEC dashboard turns that complexity into clarity.
Our platform monitors every Zai Lab quarterly earnings report 10-Q filing, Zai Lab annual report 10-K simplified, and Zai Lab 8-K material events explained the moment they hit EDGAR. Instantly see cash-runway updates, trial spend, and collaboration revenue without scrolling line-by-line. Need fast answers to “Zai Lab SEC filings explained simply” or “understanding Zai Lab SEC documents with AI”? The summary panel delivers plain-English context, key metrics, and citation links in seconds.
Stay alerted to Zai Lab insider trading Form 4 transactions. We surface Zai Lab Form 4 insider transactions real-time, flagging option exercises and open-market buys so you can assess sentiment before headlines hit. The proxy center pairs Zai Lab proxy statement executive compensation data with visual charts that benchmark R&D bonuses and equity grants against biotech peers.
- AI snapshots of pipeline milestones hidden in 10-Qs
- Side-by-side earnings trend graphs for rapid Zai Lab earnings report filing analysis
- One-click downloads of every exhibit—agreements, trial protocols, risk factors
Whether you’re gauging dilution risk, tracking Zai Lab executive stock transactions Form 4, or reviewing disclosure notes on immunology assets, Stock Titan provides the complete, continuously updated repository—decoded for actionable insight.
Zai Lab CFO Chen Yajing reported multiple transactions on Form 4 involving American Depositary Shares (ADS) on June 25-26, 2025:
- Acquired 6,250 ADSs through the vesting of Restricted Share Units (RSUs) on June 25
- Subsequently sold 2,675 ADSs at $36.132 per share on June 26 for tax coverage
- Following these transactions, directly owns 21,004 ADSs
The RSUs were granted under a four-year vesting schedule beginning June 25, 2023, with equal annual installments. Each ADS represents ten ordinary shares of the company. The automatic sale of shares was specifically conducted to cover tax obligations from the RSU vesting. The transactions were reported through an attorney-in-fact on June 27, 2025.
Form 144 Notice filed by Zai Lab officer Frazor T. Edmondson for the proposed sale of 5,877 American Depositary Shares with an aggregate market value of $212,344.83 on NASDAQ, planned for June 26, 2025.
Key details of the transaction:
- Shares were acquired through restricted stock vesting on June 25, 2025 as compensation
- Sale is being executed through Fidelity Brokerage Services LLC
- Purpose includes covering tax obligations from vested equity award distribution
Recent trading history shows Edmondson sold 6,243 shares in April 2025 for total proceeds of $218,867.09. The filing confirms no knowledge of material adverse non-public information regarding Zai Lab's operations. Total shares outstanding: 486,853,250.
Zai Lab executive Yajing Chen filed Form 144 indicating intent to sell 2,675 American Depositary Shares with an aggregate market value of $96,651.76. The sale is scheduled for June 26, 2025, through Fidelity Brokerage Services on NASDAQ.
The shares were acquired on June 25, 2025, through restricted stock vesting as part of compensation. The filing notes that the sale is partially intended to cover tax obligations from the vested equity award distribution.
Previous trading activity by Chen in the past 3 months includes:
- June 2, 2025: Sold 9,618 shares for $288,540.00
- April 4, 2025: Sold 924 shares for $30,592.25
- April 2, 2025: Sold 5,280 shares for $189,521.38
The company has approximately 486.85 million shares outstanding. The filing was signed by Wade Moss as a representative of Fidelity Brokerage Services, acting as attorney-in-fact for Chen.
Zai Lab Director and Officer Ying Du filed Form 144 indicating a proposed sale of 23,669 American Depositary Shares with an aggregate market value of $855,196.47 through Fidelity Brokerage Services. The shares were acquired through restricted stock vesting on June 25, 2025, as part of compensation.
Notable recent trading activity by Du includes:
- Multiple large sales in May 2025 totaling 196,389 shares with combined proceeds of $5.68 million
- Two smaller sales in April 2025 totaling 8,753 shares for $305,978
The filing indicates the sale is partially intended to cover tax obligations from vested equity awards. Du has certified no knowledge of undisclosed material adverse information regarding Zai Lab's operations. The company has 486.85 million shares outstanding, and the proposed sale represents approximately 0.005% of total shares.
Peter Wirth, Director at Zai Lab (ZLAB), received a grant of 10,831 American Depositary Shares (ADS) on June 18, 2025. Key details of the transaction:
- Transaction Type: Acquisition of restricted shares
- Purchase Price: $0 (granted as compensation)
- Vesting Schedule: Full vesting on June 18, 2026, contingent on continued board service
- Post-Transaction Holdings: 393,750 ADSs held directly
Each ADS represents ten ordinary shares of Zai Lab. The shares were granted as part of director compensation and are subject to a one-year vesting period. This Form 4 filing was submitted by Bruce Blefeld as attorney-in-fact on June 23, 2025.
SEC Form 4 Overview: On 18 June 2025, Zai Lab Ltd (ticker ZLAB) granted Director Michel Vounatsos an equity award of 10,831 American Depositary Shares (ADSs) at a cost basis of $0. Each ADS represents ten ordinary shares. The award consists of restricted shares that will vest in full on 18 June 2026, contingent on his continued board service. Following this grant, Vounatsos’ direct beneficial ownership increased to 50,416 ADSs. No derivative securities or sales were reported.
The filing signals routine director compensation aimed at aligning board incentives with shareholder interests; it does not disclose any purchases or sales on the open market and carries no immediate cash impact for the company.
Leon O. Moulder Jr., Director of Zai Lab, received a grant of 10,831 American Depositary Shares (ADS) on June 18, 2025. Key details of the transaction:
- The shares were acquired at $0 cost as restricted stock compensation
- The restricted shares will fully vest on June 18, 2026, contingent on Moulder's continued service on the board
- Following the transaction, Moulder directly owns 72,602 ADSs
- Each ADS represents 10 ordinary shares of Zai Lab
This Form 4 filing discloses standard equity-based director compensation, suggesting continued alignment between board member and shareholder interests. The one-year vesting period serves as a retention mechanism for the director's services.
On 06/18/2025, Zai Lab Limited (ticker: ZLAB) reported a director share transaction in a Form 4 filing. Director Richard Gaynor received 10,831 American Depositary Shares (ADS)—each ADS represents ten ordinary shares—under transaction code A (acquisition) at a price of $0, indicating a restricted share award rather than an open-market purchase.
After the grant, Gaynor’s total beneficial ownership rose to 54,899 ADS. The award will vest in full on 06/18/2026, contingent upon his continued board service. No derivative securities were involved and no shares were sold. The filing underscores ongoing equity-based compensation to align director incentives with shareholder interests, with no immediate cash impact on Zai Lab’s financials.
Form 4 Overview – Zai Lab Ltd (ZLAB)
The filing discloses that director Dr. John D. Diekman received a grant of 10,831 American Depositary Shares (ADSs) of Zai Lab on 18 June 2025. Each ADS represents ten ordinary shares. The grant was recorded with a transaction code “A”, indicating an acquisition.
Key transaction terms
- Type: Restricted stock award
- Cost basis: $0 per ADS (no cash payment required)
- Vesting: Shares vest in full on 18 June 2026, contingent on Dr. Diekman’s continued board service.
- Post-transaction holdings: 99,769 ADSs held directly after the award.
No derivative securities, sales, or option exercises were reported in this filing. The grant appears to be routine director equity compensation and does not stem from a Rule 10b5-1 trading plan.
Investor takeaway
The award modestly increases insider ownership and signals continued board alignment with shareholders, but it is not a market purchase. Because the shares are subject to a one-year vesting schedule and were issued at no cost, the filing is generally considered neutral‐to-positive in sentiment and immaterial to near-term valuation.
FAQ
What is the current stock price of Zai Lab (ZLAB)?
What is the market cap of Zai Lab (ZLAB)?
